Sfoglia per AUTORE
PERROT A
Collezione AOU Città della Salute di Torino

  

Items : 7

Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. in Blood cancer journal / Blood Cancer J. 2024 Nov 28;14(1):209. doi: 10.1038/s41408-024-01149-w.
2024
AOU Città della Salute di Torino

Richardson PG; Perrot A; Mikhael J; Martin T; Beksac M; Spicka I; Capra M; D'Agostino M; Sonneveld P; Bisht K; Fukao T; Zhang R; Tada K; Tekle C; Macé S; Klippel Z; van de Velde H; Moreau P;

30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis. in HemaSphere / Hemasphere. 2024 Nov 5;8(11):e70041. doi: 10.1002/hem3.70041. eCollection 2024 Nov.
2024
AOU Città della Salute di Torino

Ocio EM; Perrot A; Moreau P; Mateos MV; Bringhen S; Martínez-López J; Karlin L; Wang SY; Oprea C; Li Y; Kodas E; San-Miguel J;

Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research. in Haematologica / Haematologica. 2024 Jun 1;109(6):1956-1959. doi: 10.3324/haematol.2023.284282.
2024
AOU Città della Salute di Torino

Oerlemans S; De Rooij BH; Bennink C; Bullinger L; Broijl A; D'Agostino M; Laane E; Lupo-Stanghellini MT; Perrot A; Wester R; Cursaru V; Scheurer H; Vesseur J; Dalal M; Sen R; Stamm T; Ludwig H; Sonneveld P;

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. in The New England journal of medicine / N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
2024
AOU Città della Salute di Torino

Moreau P; Bladé J; Rodriguez-Otero P; Carson R; de Boer CJ; Sitthi-Amorn A; Vanquickelberghe V; van Brummelen EMJ; Vieyra D; Wang J; Liu Y; Ahmadi T; Lonergan S; Jurczyszyn A; Hajek R; Spencer A; Einsele H; Vangsted A; Silzle T; Roeloffzen W; Delforge M; Rosiñol L; Sureda Balari A; Schjesvold F; Katodritou E; van de Donk NWCJ; Nijhof IS; Mina R; Gay F; et alii...

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma. in Future oncology (London, England) / Future Oncol. 2024;20(38):3043-3063. doi: 10.1080/14796694.2024.2394323. Epub 2024 Sep 17.
2024
AOU Città della Salute di Torino

Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; van de Donk NWCJ; Katodritou E; Schjesvold F; Balari AS; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; et alii...

2023
AOU Città della Salute di Torino

Ocio EM; Perrot A; Bories P; San-Miguel JF; Blau IW; Karlin L; Martinez-Lopez J; Wang SY; Bringhen S; Marcatti M; Mateos MV; Rodriguez-Otero P; Oliva S; Nogai A; Le Roux N; Dong L; Macé S; Gassiot M; Fitzmaurice T; Oprea C; Moreau P;

Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. in American journal of hematology / Am J Hematol. 2021 Nov 1;96(11):E423-E427. doi: 10.1002/ajh.26319. Epub 2021 Sep 23.
2021
AOU Città della Salute di Torino

Schjesvold F; Bringhen S; G Richardson P; Perrot A; Leleu X; Moreau P; A Dimopoulos M; Hulin C; Tekle C; Foster MC; Poole EM; van de Velde H; Facon T;